6CM
TGTX icon

683 Capital Management’s TG Therapeutics TGTX Stock Holding History

683 Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,000
Closed -$85.4K – 253
2023
Q4 		$85.4K Buy
+5,000
New +$58.1K 0.01% 219

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

683 Capital Management's TGTX Position: Q1 2026 in Review

683 Capital Management increased its TG Therapeutics (TGTX) stake by 64% in Q1 2026, buying an estimated $6.85M and bringing the position to 590,000 shares worth $19.6M. The position accounts for 1.02% of the portfolio, ranked #25.

683 Capital Management first reported a position in TGTX in Q3 2018 and has held it in 29 quarters since. The position peaked at $28.6M in Q4 2023. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • 683 Capital Management held 590,000 shares of TG Therapeutics worth $19.6M as of Q1 2026.
  • 683 Capital Management bought 230,000 TG Therapeutics shares in Q1 2026, an estimated $6.85M.
  • TG Therapeutics made up 1.02% of 683 Capital Management's portfolio in Q1 2026, its #25 holding.
  • 683 Capital Management first reported a position in TG Therapeutics in Q3 2018 and has held it in 29 quarters since.
  • 683 Capital Management's TG Therapeutics position peaked at $28.6M in Q4 2023.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.